论文部分内容阅读
目的分析多西他赛、卡铂联合吉非替尼治疗非小细胞肺癌的临床治疗效果。方法选取本院在2013年2月~2014年2月期间确诊的80例非小细胞肺癌患者,以随机方式分为两组。观察组患者使用多西他赛、卡铂联合吉非替尼进行治疗,对照组患者仅使用吉非替尼进行治疗。3周为一周期,两周期后观察并分析比较两组患者治疗效果及各项不良反应发生情况。结果观察组治疗总有效率为67.0%,对照组为23.0%;观察组患者疾病控制率为75.0%,对照组为50.0%,P<0.05;观察组患者各项不良反应发生率显著低于对照组。结论多西他赛、卡铂联合吉非替尼治疗非小细胞肺癌疾病控制率较高,治疗效果较为满意,且不良反应较轻,患者耐受性较好,值得广泛使用。
Objective To analyze the clinical effect of docetaxel and carboplatin combined with gefitinib in the treatment of non-small cell lung cancer. Methods Eighty non-small cell lung cancer patients diagnosed in our hospital from February 2013 to February 2014 were randomly divided into two groups. Patients in the observation group were treated with docetaxel, carboplatin plus gefitinib, and patients in the control group were treated with gefitinib alone. Three weeks for a period of two weeks after the observation and analysis of the two groups of patients with treatment and the incidence of adverse reactions. Results The total effective rate was 67.0% in the observation group and 23.0% in the control group. The disease control rate was 75.0% in the observation group and 50.0% in the control group, P <0.05. The incidence of adverse reactions in the observation group was significantly lower than that in the control group group. Conclusion Docetaxel, carboplatin combined with gefitinib treatment of non-small cell lung cancer control rate is higher, the treatment effect is more satisfactory, and mild adverse reactions, patients with better tolerance, it is widely used.